TW205553B - - Google Patents

Download PDF

Info

Publication number
TW205553B
TW205553B TW081103237A TW81103237A TW205553B TW 205553 B TW205553 B TW 205553B TW 081103237 A TW081103237 A TW 081103237A TW 81103237 A TW81103237 A TW 81103237A TW 205553 B TW205553 B TW 205553B
Authority
TW
Taiwan
Prior art keywords
ser
thr
gly
leu
val
Prior art date
Application number
TW081103237A
Other languages
English (en)
Chinese (zh)
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26370596&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW205553(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from JP3095476A external-priority patent/JPH05236966A/ja
Priority claimed from JP4032084A external-priority patent/JPH05227970A/ja
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of TW205553B publication Critical patent/TW205553B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW081103237A 1991-04-25 1992-04-24 TW205553B (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP3095476A JPH05236966A (ja) 1991-04-25 1991-04-25 ヒトインターロイキン−6レセプターに対するマウスモノクローナル抗体の可変領域をコードするdna
JP4032084A JPH05227970A (ja) 1992-02-19 1992-02-19 ヒトインターロイキン−6受容体に対する再構成ヒト抗体

Publications (1)

Publication Number Publication Date
TW205553B true TW205553B (enExample) 1993-05-11

Family

ID=26370596

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081103237A TW205553B (enExample) 1991-04-25 1992-04-24

Country Status (16)

Country Link
US (3) US5795965A (enExample)
EP (1) EP0628639B1 (enExample)
JP (6) JP3370324B2 (enExample)
KR (1) KR100249937B1 (enExample)
AT (1) ATE181575T1 (enExample)
AU (2) AU668349B2 (enExample)
DE (2) DE122009000019I1 (enExample)
DK (1) DK0628639T3 (enExample)
ES (1) ES2134212T3 (enExample)
GR (1) GR3031174T3 (enExample)
HU (1) HU218140B (enExample)
LU (1) LU91556I2 (enExample)
NL (1) NL300383I2 (enExample)
RU (1) RU2139351C1 (enExample)
TW (1) TW205553B (enExample)
WO (1) WO1992019759A1 (enExample)

Families Citing this family (338)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006119A1 (en) * 1993-08-24 1995-03-02 Scotgen Limited Recombinant humanized anti-human immunodeficiency virus antibody
US5472693A (en) * 1993-02-16 1995-12-05 The Dow Chemical Company Family of anti-carcinoembryonic antigen chimeric antibodies
WO1994028159A1 (en) * 1993-05-31 1994-12-08 Chugai Seiyaku Kabushiki Kaisha Reconstructed human antibody against human interleukin-6
US5914110A (en) * 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
WO1995014041A1 (en) 1993-11-19 1995-05-26 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human medulloblastomatous cell
WO1995029690A1 (en) * 1994-04-29 1995-11-09 The Trustees Of The University Of Pennsylvania Biologically active peptides and methods of identifying the same
US8017121B2 (en) 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
EP0783893B1 (en) 1994-10-07 2012-04-04 Chugai Seiyaku Kabushiki Kaisha Inhibition of abnormal growth of synovial cells using il-6 antagonist as active ingredient
CZ298325B6 (cs) * 1994-10-21 2007-08-29 Kishimoto@Tadamitsu Farmaceutický prípravek pro prevenci nebo lécení plasmocytosy
ATE330629T1 (de) * 1995-02-13 2006-07-15 Chugai Pharmaceutical Co Ltd Inhibitor des muskelproteinabbaus enthaltend einen il-6 rezeptor antikörper
US6692742B1 (en) 1996-06-27 2004-02-17 Chugai Seiyaku Kabushiki Kaisha Remedies for myeloma to be used together with nitrogen mustard antitumor agents
BR9713294A (pt) 1996-09-26 2000-10-17 Chugai Pharmaceutical Co Ltd "anticorpos contra proteìna relacionada a hormÈnio de paratiróide humano"
UA76934C2 (en) 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
BR9811094A (pt) 1997-02-12 2000-07-18 Chugai Pharmaceutical Co Ltd Agente terapêutico para tumores linfáticos
WO1998042377A1 (fr) 1997-03-21 1998-10-01 Chugai Seiyaku Kabushiki Kaisha Substances servant a la prevention ou au traitement de maladies liees a la cellule-t sensibilisee contenant comme principe actif des antagonistes de l'il-6
ES2285769T3 (es) 1997-05-15 2007-11-16 Chugai Seiyaku Kabushiki Kaisha Remedio para la caquexia.
KR20090068385A (ko) * 1997-08-15 2009-06-26 츄가이 세이야꾸 가부시키가이샤 항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는 전신성 홍반성 낭창의 예방 및/또는 치료제
US20020187150A1 (en) * 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
PL201461B1 (pl) 1998-03-17 2009-04-30 Chugai Pharmaceutical Co Ltd Czynnik zapobiegający lub terapeutyczny do leczenia zapalenia jelita, zawierający antagonistę IL-6 jako składnik aktywny
KR20010042435A (ko) 1998-04-03 2001-05-25 나가야마 오사무 인간조직인자(티에프)에 대한 인간형화항체 및인간형화항체의 제조방법
CA2341239C (en) 1998-08-24 2011-01-04 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for pancreatitis comprising il-6 antagonist as an active ingredient
HK1044171B (zh) 1998-11-27 2016-03-24 Ucb Pharma S.A. 增加骨矿化的组合物和方法
US7696325B2 (en) 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
WO2001016166A2 (en) * 1999-08-27 2001-03-08 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Polypeptides, comprising il-6 ligand-binding receptor domains, and related nucleic acids, antibodies, compositions, and methods of use
DE60045638D1 (de) 1999-10-01 2011-03-31 Chugai Pharmaceutical Co Ltd Vermeidung und behandlung von krankheiten, die mit der blutgerinnung in zusammenhang stehen
GB0002666D0 (en) 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
EP1283057B2 (en) 2000-04-28 2012-05-30 Chugai Seiyaku Kabushiki Kaisha Cell proliferation inhibitors
WO2002013860A1 (en) 2000-08-11 2002-02-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
ATE391174T1 (de) 2000-10-20 2008-04-15 Chugai Pharmaceutical Co Ltd Modifizierter tpo-agonisten antikörper
EP1327681A4 (en) 2000-10-20 2004-09-01 Chugai Pharmaceutical Co Ltd Degraded agonist antibodies
CN1308447C (zh) 2000-10-20 2007-04-04 中外制药株式会社 低分子化的激动剂抗体
EP1334731B1 (en) 2000-10-25 2008-02-27 Chugai Seiyaku Kabushiki Kaisha Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist
WO2002036165A1 (fr) * 2000-10-27 2002-05-10 Chugai Seiyaku Kabushiki Kaisha Agent à base d'antagoniste d'il-6, faisant baisser le niveau des mmp-3 dans le sang
AU2000279624A1 (en) * 2000-10-27 2002-05-15 Chugai Seiyaku Kabushiki Kaisha Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient
WO2002064159A1 (fr) 2001-02-07 2002-08-22 Chugai Seiyaku Kabushiki Kaisha Remedes contre les tumeurs affectant les organes hematopoietiques
WO2002069904A2 (en) * 2001-03-02 2002-09-12 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease
JP4391086B2 (ja) 2001-03-09 2009-12-24 中外製薬株式会社 タンパク質精製方法
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
JP4236934B2 (ja) 2001-04-17 2009-03-11 中外製薬株式会社 界面活性剤の定量方法
US20100056762A1 (en) * 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
EP2163256B1 (en) * 2001-05-11 2015-09-02 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
WO2003068259A1 (fr) 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
GB0208041D0 (en) * 2002-04-08 2002-05-22 Lonza Biologics Plc Method of culturing animal cells
WO2004022597A1 (ja) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化n端ペプチドに対する抗体
JPWO2003090779A1 (ja) * 2002-04-25 2005-08-25 中外製薬株式会社 肺癌治療薬
CA2488441C (en) * 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
EP1541165A4 (en) 2002-08-27 2009-06-24 Chugai Pharmaceutical Co Ltd METHOD FOR STABILIZING PROTEIN PREPARATION
DK1561756T3 (en) 2002-09-11 2016-02-15 Chugai Pharmaceutical Co Ltd PROCEDURE FOR CLEANING PROTEIN.
NZ541928A (en) * 2003-02-24 2009-06-26 Chugai Pharmaceutical Co Ltd Remedy for spinal injury containing interleukin-6 antagonist
JP2004279086A (ja) 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
AU2004262640B2 (en) 2003-06-16 2010-12-23 Ucb Manufacturing, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
WO2005005636A1 (ja) 2003-07-15 2005-01-20 Chugai Seiyaku Kabushiki Kaisha 形質転換細胞によるIgMの産生とその定量方法
RU2554942C2 (ru) 2003-10-17 2015-07-10 Тугаи Сейяку Кабусики Кайся Терапевтический агент для мезотелиомы
JPWO2005054467A1 (ja) 2003-12-03 2007-12-06 中外製薬株式会社 哺乳類βアクチンプロモーターを利用した発現系
AR048210A1 (es) * 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
US8617550B2 (en) 2003-12-19 2013-12-31 Chugai Seiyaku Kabushiki Kaisha Treatment of vasculitis with IL-6 antagonist
JP2008505054A (ja) * 2004-02-11 2008-02-21 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Il−6アンタゴニストで骨関節炎を治療する方法
AU2005214988A1 (en) * 2004-02-17 2005-09-01 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
US7767792B2 (en) * 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
WO2005090405A1 (ja) * 2004-03-24 2005-09-29 Chugai Seiyaku Kabushiki Kaisha インターロイキン-6受容体に対するヒト型化抗体のサブタイプ
AR048335A1 (es) * 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
GB0410627D0 (en) * 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
WO2006046661A1 (ja) * 2004-10-28 2006-05-04 Osaka University インターロイキン-6阻害剤
CN101061215A (zh) 2005-01-05 2007-10-24 中外制药株式会社 细胞的培养方法及其应用
CA2599115A1 (en) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. Novel combinational use of sulfonamide compound
EP3623473A1 (en) * 2005-03-31 2020-03-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
US9493569B2 (en) 2005-03-31 2016-11-15 Chugai Seiyaku Kabushiki Kaisha Structural isomers of sc(Fv)2
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
KR101360671B1 (ko) 2005-06-10 2014-02-07 추가이 세이야쿠 가부시키가이샤 sc(Fv)2를 함유하는 의약조성물
WO2006132363A1 (ja) 2005-06-10 2006-12-14 Chugai Seiyaku Kabushiki Kaisha メグルミンを含有するタンパク質製剤の安定化剤、およびその利用
CN105017423B (zh) * 2005-08-11 2019-06-04 阿皮·马托西安-罗杰斯 用于自身免疫性疾病治疗和诊断的TCR-V-β相关肽
CA2625773C (en) 2005-10-14 2015-05-12 Fukuoka University Inhibition of interleukin-6 (il-6) receptor promotes pancreatic islet transplantation
RU2450830C2 (ru) 2005-10-21 2012-05-20 Чугаи Сейяку Кабусики Кайся Средства для лечения кардиопатии
US8679490B2 (en) 2005-11-07 2014-03-25 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
JP5398987B2 (ja) 2005-11-14 2014-01-29 セルミド リミテッド 調節性t細胞の機能異常に基づく疾患の治療方法及び予防方法
AR057582A1 (es) * 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
AR057941A1 (es) * 2005-11-25 2007-12-26 Univ Keio Agentes terapeuticos para el cancer de prostata
WO2007074880A1 (ja) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
CN104189907A (zh) 2006-01-27 2014-12-10 学校法人庆应义塾 伴有脉络膜血管生成的疾病的治疗药
WO2007108505A1 (ja) 2006-03-22 2007-09-27 Chugai Seiyaku Kabushiki Kaisha エリスロポエチン溶液製剤
ES2654040T3 (es) 2006-03-31 2018-02-12 Chugai Seiyaku Kabushiki Kaisha Método de modificación de anticuerpos para la purificación de anticuerpos biespecíficos
CN101479381B (zh) 2006-03-31 2015-04-29 中外制药株式会社 调控抗体血液动力学的方法
EP2025346B1 (en) 2006-04-07 2016-08-10 Osaka University Muscle regeneration promoter
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
NZ572565A (en) * 2006-05-25 2011-04-29 Glaxo Group Ltd Modified humanised anti-interleukin-18 antibodies
ES2398076T3 (es) * 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
US7919092B2 (en) * 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
CA2655289C (en) 2006-06-21 2016-08-23 Oncotherapy Science, Inc. Tumor-targeting monoclonal antibodies to fzd10 and uses thereof
CA2666599A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2008042611A2 (en) * 2006-09-29 2008-04-10 Centocor, Inc. Method of using il6 antagonists with mitoxantrone for prostate cancer
US9725514B2 (en) 2007-01-23 2017-08-08 Shinshu University Chronic rejection inhibitor
US8088617B2 (en) 2007-01-24 2012-01-03 Oncomed Pharmaceuticals, Inc. Antibodies that bind the glutamate ligand binding region of Notch1
WO2008091701A2 (en) 2007-01-25 2008-07-31 Dana-Farber Cancer Institute Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
CL2008000719A1 (es) 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
KR101829776B1 (ko) * 2007-05-21 2018-02-19 앨더바이오 홀딩스 엘엘씨 Il-6에 대한 항체 및 이의 용도
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US7906117B2 (en) * 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
JP5859202B2 (ja) * 2007-05-21 2016-02-10 アルダーバイオ・ホールディングズ・エルエルシー 新規のウサギ抗体ヒト化方法及びヒト化ウサギ抗体
JP5142265B2 (ja) * 2007-05-28 2013-02-13 独立行政法人産業技術総合研究所 抗モータリン抗体のパラトープ及びエピトープ
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
JP5424330B2 (ja) * 2007-07-26 2014-02-26 国立大学法人大阪大学 インターロイキン6受容体阻害剤を有効成分とする眼炎症疾患治療剤
MX2010001335A (es) 2007-07-31 2010-06-02 Lifescan Inc Diferenciacion de celulas madre embrionarias humanas.
MX2010001757A (es) 2007-08-14 2010-09-14 Ludwig Inst Cancer Res Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo.
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
EP3127921A1 (en) * 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
WO2009041613A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗体定常領域改変体
BRPI0817250A2 (pt) 2007-09-26 2014-06-17 Chugai Pharmaceutical Co Ltd Anticorpo anti-receptor da il-6.
EP2196220B1 (en) 2007-10-02 2014-12-03 Chugai Seiyaku Kabushiki Kaisha Inhibting anti-IL-6 receptor antibody for treating graft-versus-host disease
BRPI0818674B1 (pt) 2007-10-15 2023-01-17 Chugai Seiyaku Kabushiki Kaisha Métodos para produção de um anticorpo inteiro ou de um fragmento do mesmo e para preparação de fármacos, bem como vetor recombinante
ES2372463T3 (es) 2007-11-27 2012-01-20 Lifescan, Inc. Diferenciación de células madre embrionarias humanas.
BRPI0821110B8 (pt) 2007-12-05 2021-05-25 Chugai Pharmaceutical Co Ltd anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
US20110262425A1 (en) 2007-12-12 2011-10-27 National Cancer Center Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
WO2009095489A2 (en) * 2008-02-01 2009-08-06 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
CN102046779A (zh) 2008-02-21 2011-05-04 森托科尔奥索生物科技公司 用于细胞粘附、培养和分离的方法、表面改性培养板和组合物
HUE067049T2 (hu) 2008-04-11 2024-09-28 Chugai Pharmaceutical Co Ltd Két vagy több antigén-molekulát ismétlõdõen megkötni képes antigénkötõ molekula
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
AU2009241589B2 (en) * 2008-04-29 2013-10-10 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CN102089326B (zh) 2008-05-13 2014-12-31 诺维莫尼公司 抗白细胞介素-6/白细胞介素-6受体的抗体及其使用方法
MX2010013236A (es) 2008-06-03 2011-02-24 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
TW201008580A (en) 2008-06-03 2010-03-01 Abbott Lab Dual variable domain immunoglobulin and uses thereof
CN104906581A (zh) 2008-06-05 2015-09-16 国立研究开发法人国立癌症研究中心 神经浸润抑制剂
US8188235B2 (en) * 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
JP5734183B2 (ja) 2008-06-30 2015-06-17 ヤンセン バイオテツク,インコーポレーテツド 多能性幹細胞の分化
KR20110031369A (ko) 2008-07-08 2011-03-25 아보트 러보러터리즈 프로스타글란딘 e2 이원 가변 도메인 면역글로불린 및 이의 용도
CN102112490B (zh) * 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
CN102272291B (zh) 2008-10-31 2018-01-16 詹森生物科技公司 人胚胎干细胞向胰腺内分泌谱系的分化
MX2011005289A (es) 2008-11-20 2011-06-01 Centocor Ortho Biotech Inc Metodos y composiciones para union y cultivo celular sobre sustratos planares.
AU2009316580B2 (en) 2008-11-20 2016-04-14 Janssen Biotech, Inc. Pluripotent stem cell culture on micro-carriers
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
EP3674317B1 (en) 2009-03-19 2024-12-11 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
MX2011010681A (es) 2009-04-10 2012-01-20 Ablynx Nv Secuencias mejoradas de aminoacidos dirigidas contra il-6r y polipeptidos que comprenden el mismo para el tratamiento de enfermedades y trastornos relacionados con il-6r.
US10618964B2 (en) 2009-04-10 2020-04-14 Ablynx N.V. Nanobody against IL-6R
MX2011011670A (es) * 2009-05-01 2011-11-18 Abbott Lab Inmunoglobulinas de dominio variable dual y usos de las mismas.
PE20120562A1 (es) 2009-05-15 2012-06-06 Chugai Pharmaceutical Co Ltd Anticuerpo anti-axl
JP6219568B2 (ja) 2009-07-20 2017-10-25 ヤンセン バイオテツク,インコーポレーテツド ヒト胚性幹細胞の分化
SG10201404340TA (en) 2009-07-31 2014-10-30 Shin Maeda Cancer metastasis inhibitor
WO2011037158A1 (ja) 2009-09-24 2011-03-31 中外製薬株式会社 抗体定常領域改変体
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
AU2010306677B2 (en) * 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
PL3202785T3 (pl) 2009-10-26 2024-08-12 F. Hoffmann-La Roche Ag Sposób wytwarzania glikozylowanej immunoglobuliny
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011066369A2 (en) 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antagonists of il-6 to raise albumin and/or lower crp
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
EP2519542B1 (en) 2009-12-28 2018-10-10 OncoTherapy Science, Inc. Anti-cdh3 antibodies and uses thereof
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
AU2011205316B2 (en) 2010-01-13 2015-05-28 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
BR112012022145A2 (pt) 2010-03-01 2020-10-06 Janssen Biotech, Inc. métodos para purificar células derivadas de células-tronco pluripotentes
JP5889181B2 (ja) 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
CN102869381A (zh) 2010-03-04 2013-01-09 大日本住友制药株式会社 用于炎性肠病的药物
EP2552967A4 (en) 2010-04-02 2014-10-08 Amunix Operating Inc BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE
WO2011128096A1 (en) 2010-04-16 2011-10-20 Roche Diagnostics Gmbh Polymorphism markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
KR101986176B1 (ko) 2010-05-12 2019-06-05 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
RS63800B1 (sr) 2010-05-28 2022-12-30 Chugai Pharmaceutical Co Ltd Poboljšanje antitumorskog odgovora t ćelije
JP5904552B2 (ja) 2010-05-28 2016-04-13 国立研究開発法人国立がん研究センター 膵癌治療剤
JPWO2011152503A1 (ja) 2010-06-02 2013-08-01 大日本住友製薬株式会社 自己免疫疾患またはアレルギー疾患の治療剤
CA2801107A1 (en) 2010-06-07 2011-12-15 F. Hoffman-La Roche Ag Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
AR081434A1 (es) * 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
JP2013537415A (ja) 2010-08-03 2013-10-03 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SG187938A1 (en) 2010-08-26 2013-04-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
CN103221536B (zh) 2010-08-31 2016-08-31 詹森生物科技公司 人胚胎干细胞的分化
SMT202200321T1 (it) 2010-10-01 2022-09-14 Modernatx Inc Acidi ribonucleici contenenti n1-metil-pseudouracili e loro usi
US9238690B2 (en) 2010-10-29 2016-01-19 Immunogen, Inc. Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
EP2632490A4 (en) 2010-10-29 2014-10-22 Immunogen Inc NOVEL MOLECULES BINDING TO THE EGF RECEPTOR AND IMMUNOCONJUGATES THEREOF
KR20130086628A (ko) 2010-11-08 2013-08-02 제넨테크, 인크. 피하 투여용 항―il―6 수용체 항체
KR102099580B1 (ko) 2010-11-17 2020-04-10 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
ES2847891T3 (es) 2010-11-23 2021-08-04 Vitaeris Inc Anticuerpos anti-IL-6 para el tratamiento de la mucositis oral
CN103328632A (zh) 2010-11-30 2013-09-25 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
RU2604139C2 (ru) 2011-01-28 2016-12-10 Санофи Байотекнолоджи Фармацевтические композиции, содержащие антитела к pcsk9 человека
EP3604330A1 (en) 2011-02-25 2020-02-05 Chugai Seiyaku Kabushiki Kaisha Fcgammariib-specific fc antibody
US9133272B2 (en) 2011-03-01 2015-09-15 Amgen Inc. Bispecific binding agents
BR112013024493A2 (pt) 2011-03-25 2018-06-26 Amgen Inc. cristais de anticorpo antiesclerostina e formulações dos mesmos
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
ES2685821T3 (es) 2011-06-10 2018-10-11 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence Anticuerpos anti-ricina y sus usos
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
US8980266B2 (en) 2011-06-28 2015-03-17 Inhibrx, Llc Serpin fusion polypeptides and methods of use thereof
US9574005B2 (en) 2011-07-19 2017-02-21 Chugai Seiyaku Kabushiki Kaisha Stable Protein-containing preparation containing argininamide or analogous compound thereof
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
WO2013017656A1 (en) 2011-08-02 2013-02-07 Medizinische Universität Wien Antagonists of ribonucleases for treating obesity
EP2739652B1 (en) 2011-08-04 2017-04-05 Medizinische Universität Innsbruck Cahgt1p inhibitors for use in the treatment of candidiasis
HUE039786T2 (hu) 2011-08-04 2019-02-28 Amgen Inc Csonthiány-defektusok kezelési módszere
EP3235557B1 (en) 2011-09-01 2025-04-30 Chugai Seiyaku Kabushiki Kaisha PROCESS FOR PREPARING A COMPOSITION COMPRISING HIGHLY CONCENTRATED ANTIBODIES BY ULTRAFILTRATION
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013041722A1 (en) 2011-09-23 2013-03-28 Ablynx Nv Prolonged inhibition of interleukin-6 mediated signaling
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之FcRn結合域的治療性抗原結合分子
DE102011083811A1 (de) * 2011-09-30 2013-04-04 Airbus Operations Gmbh Sitzvorrichtung für ein Luft- oder Raumfahrzeug
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドModernaTX,Inc. 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
WO2013059548A1 (en) 2011-10-19 2013-04-25 Sanofi Compositions and methods for treating cancer using jak2 inhibitor
BR112014009925B1 (pt) 2011-10-28 2022-09-20 Teva Pharmaceuticals Australia Pty Ltd Construtores de polipeptídeos e seus usos
JO3370B1 (ar) 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
KR20140105765A (ko) 2011-11-21 2014-09-02 이뮤노젠 아이엔씨 EGfr 항체 세포독성제 접합체에 의한 EGfr 치료에 내성을 나타내는 종양의 치료 방법
ES2719108T3 (es) * 2011-11-30 2019-07-08 Abbvie Biotechnology Ltd Vectores y células hospedadoras que comprenden un promotor de SV40 modificado para la expresión de proteínas
ES2827787T3 (es) * 2011-12-13 2021-05-24 Nordic Nanovector Asa Anticuerpos HH1 anti-CD37 quiméricos terapéuticos
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
CA2860107C (en) 2011-12-22 2021-06-01 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into single hormonal insulin positive cells
EA202091676A1 (ru) 2011-12-28 2021-01-29 Эмджен Инк. Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
UY34558A (es) 2011-12-30 2013-07-31 Abbvie Inc Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
SG10201710574UA (en) 2012-03-15 2018-02-27 Janssen Biotech Inc Human anti-cd27 antibodies, methods and uses
JP2015513913A (ja) 2012-04-02 2015-05-18 モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. 修飾ポリヌクレオチド
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CA2865676C (en) 2012-04-17 2020-03-10 F.Hoffmann-La Roche Ag Method for the expression of polypeptides using modified nucleic acids
KR101510302B1 (ko) * 2012-05-11 2015-04-10 가톨릭대학교 산학협력단 Il-6 수용체를 표적으로 하는 항체가 생성되도록 미니서클 벡터를 통해 형질전환된 줄기세포 치료제
KR101510830B1 (ko) 2012-05-11 2015-04-10 가톨릭대학교 산학협력단 생리활성 단백질을 발현하는 미니서클을 이용하여 형질전환된 줄기세포를 통한 치료법
KR101510831B1 (ko) * 2012-05-11 2015-04-10 가톨릭대학교 산학협력단 항 il-6r 및 tnfr2을 포함하는 이중특이적 단백질을 발현하는 미니서클 벡터를 포함하는 줄기세포 치료제
ES2897649T3 (es) 2012-06-08 2022-03-02 Janssen Biotech Inc Diferenciación de células madre embrionarias humanas en células endocrinas pancreáticas
CN104619342A (zh) 2012-07-05 2015-05-13 Ucb医药有限公司 骨疾病的治疗
US10822420B2 (en) 2012-09-13 2020-11-03 Chugai Seiyaku Kabushiki Kaisha Gene knock-in non-human animal
US9487590B2 (en) 2012-09-25 2016-11-08 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
TW202037609A (zh) 2012-11-01 2020-10-16 美商艾伯維有限公司 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
HK1217727A1 (zh) 2012-12-31 2017-01-20 Janssen Biotech, Inc. 用於分化成胰腺內分泌細胞的人多能細胞的懸浮和群集
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
EP4219683A1 (en) 2012-12-31 2023-08-02 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells using hb9 regulators
EP2938724B1 (en) 2012-12-31 2020-10-28 Janssen Biotech, Inc. Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells
CA2904448A1 (en) 2013-03-15 2014-09-18 Tariq Ghayur Dual specific binding proteins directed against il-1.beta. and/or il-17
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
SG11201508923VA (en) 2013-04-29 2015-11-27 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
EP3009518B1 (en) * 2013-06-11 2020-08-12 National Center of Neurology and Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
CN105378480B (zh) 2013-07-04 2018-06-12 豪夫迈·罗氏有限公司 检测血清样品中抗药物抗体的干扰抑制性免疫测定
CA2925256C (en) 2013-09-27 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
MX2016004249A (es) 2013-10-03 2016-11-08 Moderna Therapeutics Inc Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad.
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
BR112016013347B1 (pt) 2013-12-26 2023-12-12 Mitsubishi Tanabe Pharma Corporation Anticorpo monoclonal humano neutralizante anti-il-33, composição farmacêutica, inibidor da expressão de citocinas, molécula de ácido nucleico, vetor, célula bacteriana transgênica, método de produção e uso dos mesmos
EP3088411B1 (en) 2013-12-27 2025-09-24 Chugai Seiyaku Kabushiki Kaisha Method for purifying antibody having low isoelectric point
EP2898896A1 (en) 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents for use in the treatment of retinal inflammation
WO2015116852A1 (en) 2014-01-29 2015-08-06 Regeneron Pharmaceuticals, Inc. Methods for treating rheumatoid arthritis by administering an il-6r antibody
CR20210097A (es) 2014-03-21 2022-04-27 Abbvie Inc Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
DK3143127T3 (da) 2014-05-16 2021-09-13 Janssen Biotech Inc Anvendelse af små molekyler til at forstærke mafa-ekspression i endokrine pankreasceller
EP4056993A1 (en) 2014-08-20 2022-09-14 Chugai Seiyaku Kabushiki Kaisha Method for measuring viscosity of protein solution
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
CN107074954A (zh) 2014-10-21 2017-08-18 埃博灵克斯股份有限公司 Il‑6r相关疾病的治疗
IL251822B2 (en) 2014-10-29 2023-03-01 Teva Pharmaceuticals Australia Pty Ltd Variants of interferon alpha-2-b
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
WO2016100233A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
CA3008162A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
AR103162A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y métodos para su uso
TWI779010B (zh) 2014-12-19 2022-10-01 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法
CN114773470A (zh) 2015-02-05 2022-07-22 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用
SG11201705093UA (en) 2015-02-27 2017-07-28 Chugai Pharmaceutical Co Ltd Composition for treating il-6-related diseases
AR104050A1 (es) 2015-03-26 2017-06-21 Chugai Pharmaceutical Co Ltd Proceso de producción con iones de cobre controlados
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
JP6875683B2 (ja) 2015-05-19 2021-05-26 国立研究開発法人国立精神・神経医療研究センター 多発性硬化症(ms)患者の新規治療適用判断方法
JP7128460B2 (ja) 2015-06-04 2022-08-31 国立研究開発法人国立精神・神経医療研究センター Il-6阻害剤を有効成分とする精神疾患治療剤
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗vegf、pdgf及/或其受體之結合蛋白
PL3337828T3 (pl) 2015-08-18 2026-01-26 Regeneron Pharmaceuticals, Inc. Przeciwciała hamujące anty-pcsk9 do leczenia pacjentów z hiperlipidemią poddawaną aferezie lipoproteinowej
JP7272794B2 (ja) 2015-11-03 2023-05-12 サノフィ・バイオテクノロジー ブドウ膜炎および黄斑浮腫の処置のためのil6r抗体を含む組成物およびそれを使用する方法
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
KR102784832B1 (ko) 2015-12-28 2025-03-21 추가이 세이야쿠 가부시키가이샤 Fc 영역 함유 폴리펩타이드의 정제를 효율화하기 위한 방법
WO2017147169A1 (en) 2016-02-22 2017-08-31 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin a analogues or metabolites, and estradiol metabolites
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
TW202214700A (zh) 2016-03-14 2022-04-16 日商中外製藥股份有限公司 用於癌之治療的細胞傷害誘導治療劑
MA45479A (fr) 2016-04-14 2019-02-20 Janssen Biotech Inc Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
WO2017188356A1 (ja) 2016-04-28 2017-11-02 中外製薬株式会社 抗体含有製剤
JP6527643B2 (ja) 2016-08-05 2019-06-05 中外製薬株式会社 Il−8関連疾患の治療用又は予防用組成物
CN109963590B (zh) 2016-09-02 2024-03-15 加利福尼亚大学董事会 涉及白介素-6受体α结合单链可变片段的方法和组合物
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
EP3518891A1 (en) 2016-09-27 2019-08-07 Fresenius Kabi Deutschland GmbH Liquid pharmaceutical composition
KR102051177B1 (ko) * 2016-10-19 2019-12-17 주식회사 엘지화학 전압 분배를 이용한 스위치 진단 장치 및 방법
EP3532029B1 (en) 2016-10-31 2021-04-28 Fresenius Kabi Deutschland GmbH Liquid pharmaceutical composition
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
CN110603057A (zh) 2017-03-17 2019-12-20 俄亥俄州创新基金会 用于递送化学预防剂的纳米颗粒
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法
CN107098969B (zh) * 2017-06-28 2018-10-12 武汉波睿达生物科技有限公司 一种治疗hiv感染的嵌合抗原受体的重组基因构建及其应用
CN115920031A (zh) 2017-08-31 2023-04-07 田边三菱制药株式会社 含有il-33拮抗剂的子宫内膜异位症治疗剂
EP3683234A1 (en) 2017-09-13 2020-07-22 Jiangsu Hengrui Medicine Co., Ltd. Il-6r antibody and antigen binding fragment thereof and medical use
WO2019078344A1 (ja) 2017-10-20 2019-04-25 学校法人兵庫医科大学 抗il-6受容体抗体を含有する術後の癒着を抑制するための医薬組成物
MX2020003472A (es) 2017-11-01 2020-08-03 Chugai Pharmaceutical Co Ltd Variante e isoforma de anticuerpos con actividad biologica reducida.
TWI822728B (zh) 2018-01-31 2023-11-21 加藤元一 含有il-6抑制劑的哮喘治療劑
EP3765494A4 (en) 2018-03-15 2022-03-23 Chugai Seiyaku Kabushiki Kaisha ANTI-DENGUE VIRUS ANTIBODIES WITH CROSS-REACTIVITY AGAINST ZIKA VIRUS AND METHODS OF USE
IL316596A (en) 2018-03-30 2024-12-01 Amgen Inc C-terminal antibody variants
EP3797752B1 (en) 2018-05-21 2024-07-17 Chugai Seiyaku Kabushiki Kaisha Lyophilized formulation sealed in glass container
WO2019230725A1 (ja) 2018-05-28 2019-12-05 中外製薬株式会社 充填ノズル
CN112955222A (zh) 2018-08-29 2021-06-11 里珍纳龙药品有限公司 用于治疗患有类风湿性关节炎的个体的方法和组合物
US20220096548A1 (en) * 2019-01-07 2022-03-31 Hunan Siweikang Therapeutics Co. Ltd. Modified immune cells co-expressing chimeric antigen receptor and il-6 antagonist for reducing toxicity and uses thereof in adoptive cell therapy
TW202521583A (zh) 2019-01-31 2025-06-01 法商賽諾菲生物技術公司 用於治療幼年原發性關節炎之組成物及方法
KR20210144795A (ko) 2019-03-29 2021-11-30 추가이 세이야쿠 가부시키가이샤 항il-6 수용체 항체를 함유하는 bbb 기능 저하의 억제제
US20220177978A1 (en) 2019-04-02 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
SG11202110986YA (en) 2019-04-10 2021-11-29 Chugai Pharmaceutical Co Ltd Method for purifying fc region-modified antibody
TWI868126B (zh) 2019-04-17 2025-01-01 國立大學法人廣島大學 以組合投予il-6 抑制劑與ccr2 抑制劑為特徵之泌尿器官癌的治療劑
KR20220088829A (ko) 2019-04-24 2022-06-28 사노피 바이오테크놀로지 류마티스 관절염의 진단 및 치료 방법
EP3976644A4 (en) 2019-05-31 2022-12-14 The Johns Hopkins University BI-SPECIFIC LIAISONS
TW202110892A (zh) 2019-06-04 2021-03-16 法商賽諾菲生物技術公司 治療具有類風濕性關節炎的個體中疼痛之組成物及方法
JP2022537555A (ja) 2019-06-20 2022-08-26 武田薬品工業株式会社 ウイルスベースの遺伝子療法による治療方法
CN110483640B (zh) * 2019-07-16 2020-05-01 北京汇智和源生物技术有限公司 白介素-6r的人源化单克隆抗体、其编码基因及应用
AU2021231765A1 (en) 2020-03-03 2022-10-06 Redona Therapeutics, Inc. Compounds targeting RNA-binding proteins or RNA-modifying proteins
WO2021194861A1 (en) 2020-03-23 2021-09-30 Genentech, Inc. Biomarkers for predicting response to il-6 antagonist in covid-19 pneumonia
EP4107184A1 (en) 2020-03-23 2022-12-28 Genentech, Inc. Method for treating pneumonia, including covid-19 pneumonia, with an il6 antagonist
JP2023518812A (ja) 2020-03-23 2023-05-08 ジェネンテック, インコーポレイテッド Covid19肺炎を治療するための、トシリズマブとレムデシビルとの組み合わせ
WO2021211006A1 (en) 2020-04-13 2021-10-21 Federal State Budgetary Institution Center Of Biomedical Technologies Of Federal Medical And Biological Agency Inhaled hexapeptide for treating interleukin-6 related respiratory diseases
JP2023520249A (ja) 2020-05-15 2023-05-16 エフ. ホフマン-ラ ロシュ アーゲー 非経口タンパク質溶液中の可視粒子形成の防止方法
EP4153626A4 (en) * 2020-05-18 2024-09-11 Biosion, Inc. IL6R-BINDING ANTIBODIES AND USES THEREOF
WO2022005321A1 (en) 2020-06-29 2022-01-06 Federal State Budgetary Institution Scientific center of biomedical technologies of Federal Medical and Biological Agency Inhaled tocilizumab for treating interleukin-6 related respiratory diseases
KR20220028972A (ko) 2020-08-31 2022-03-08 (주)셀트리온 안정한 약제학적 제제
US20230357418A1 (en) 2020-09-17 2023-11-09 Genentech, Inc. Results of empacta: a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of tocilizumab in hospitalized patients with covid-19 pneumonia
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
WO2022165419A1 (en) 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Methods for increasing t-cell function
US20240158518A1 (en) 2021-03-12 2024-05-16 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for treatment or prevention of myasthenia gravis
CA3221924A1 (en) 2021-06-11 2022-12-15 Genentech, Inc. Method for treating chronic obstructive pulmonary disease with an st2 antagonist
KR20240082388A (ko) 2021-10-08 2024-06-10 추가이 세이야쿠 가부시키가이샤 프리필드 시린지 제제의 조제 방법
WO2023210670A1 (ja) 2022-04-26 2023-11-02 中外製薬株式会社 医薬製剤含有フィルター内蔵シリンジ
US20240190978A1 (en) 2022-11-15 2024-06-13 CSBioAsset LLC Compositions and methods for immunomodulatory bifunctional fusion molecules
TW202444922A (zh) 2023-03-31 2024-11-16 國立大學法人大阪大學 用於預測敗血症患者之預後的生物標記及其用途
WO2024214811A1 (ja) 2023-04-14 2024-10-17 中外製薬株式会社 タンパク質含有医薬製剤の安定化方法
WO2025198912A1 (en) 2024-03-21 2025-09-25 Hoffmann-La Roche Inc. Methods of treating myasthenia gravis
HUP2400216A1 (hu) 2024-04-17 2025-10-28 Richter Gedeon Nyrt N-terminális glutamint tartalmazó immunglobulinok tisztítására szolgáló eljárások

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4304583A (en) * 1980-06-02 1981-12-08 Corning Glass Works Process for drying optical waveguide preforms
JPS6147500A (ja) * 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5082782A (en) 1988-12-27 1992-01-21 Worcester Polytechnic Institute Production of horseshoe crab amebocytes in vitro
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5216128A (en) * 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
CA2021594C (en) * 1989-07-20 2002-01-08 Tadamitsu Kishimoto Antibody to human interleukin-6 receptor
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
FR2943539B1 (fr) 2009-03-31 2011-07-22 Ethypharm Sa Composition pharmaceutique comprenant un macrolide immunosuppresseur de la famille des limus.
EP2409607A1 (de) 2010-07-20 2012-01-25 Josef Kurz Schuhlöffel

Also Published As

Publication number Publication date
ES2134212T3 (es) 1999-10-01
GR3031174T3 (en) 1999-12-31
ATE181575T1 (de) 1999-07-15
HU9303002D0 (en) 1994-01-28
DK0628639T3 (da) 2000-01-24
US20050142635A1 (en) 2005-06-30
KR100249937B1 (ko) 2000-04-01
JP3616087B2 (ja) 2005-02-02
AU1674092A (en) 1992-12-21
RU2139351C1 (ru) 1999-10-10
DE122009000019I1 (de) 2009-07-16
JP2007082560A (ja) 2007-04-05
JP2000116391A (ja) 2000-04-25
US5795965A (en) 1998-08-18
HU218140B (hu) 2000-06-28
LU91556I2 (fr) 2009-06-24
DE69229482D1 (de) 1999-07-29
JP2001083151A (ja) 2001-03-30
AU668349B2 (en) 1996-05-02
DE69229482T2 (de) 1999-11-18
JP3370324B2 (ja) 2003-01-27
NL300383I1 (nl) 2009-06-02
JP3913965B2 (ja) 2007-05-09
JP2004045433A (ja) 2004-02-12
AU5621396A (en) 1996-10-24
NL300383I2 (nl) 2010-02-01
JP2008073049A (ja) 2008-04-03
EP0628639A4 (en) 1994-12-28
US7479543B2 (en) 2009-01-20
US5817790A (en) 1998-10-06
AU692100B2 (en) 1998-05-28
EP0628639B1 (en) 1999-06-23
EP0628639A1 (en) 1994-12-14
HUT70258A (en) 1995-09-28
WO1992019759A1 (fr) 1992-11-12
JP3176598B2 (ja) 2001-06-18

Similar Documents

Publication Publication Date Title
TW205553B (enExample)
TWI718206B (zh) Pd-l1抗體、其抗原結合片段及其醫藥用途
DE69734109T2 (de) Humanisierung von anti-carcinoembryonalen Antigen anti-idiotypischen Antikörper und dessen Verwendung als Tumorvakzin und zur Markierung
AU2013329381B2 (en) Antibodies recognizing alpha-synuclein
TWI717678B (zh) Pd-l1抗體、其抗原結合片段及醫藥用途
CN114502591B (zh) 靶向bcma的抗体、双特异性抗体及其用途
DE69331903T2 (de) Veränderte Antikörper, damit zusammenhängende Produkte und Verfahren
EP3689909A1 (en) Tigit antibody, antigen-binding fragment thereof, and medical use thereof
US20130071385A1 (en) Monoclonal antibodies
TWI843799B (zh) 抗pd-1抗體、其抗原結合片段及醫藥用途
CN109952317A (zh) 使用pd-1结合蛋白治疗免疫病症的方法
US12479922B2 (en) Humanized monoclonal antibody targeting BCMA and having human monkey cross-reactivity
TW526206B (en) Reshaped human antibody to human medulloblastoma cells
EP1478667A1 (en) Anti-human tenascin monoclonal antibody
TW202128765A (zh) 一種雙特異性抗體
DE69504959T2 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
WO2024160076A1 (zh) 针对人il-36r和/或人il-1r3的多种抗体及其用途
CA3152860A1 (en) Anti-tfpi monoclonal antibodies
AU2014200771B2 (en) Monoclonal antibodies
AU2016216708A1 (en) Monoclonal antibodies
TW202542192A (zh) 靶向cd3的抗體及其應用
AU2009288700B2 (en) Monoclonal antibodies
HK40003309A (en) ANTIBODIES THAT RECOGNIZE α-SYNUCLEIN
WALDMANN Framework mutated antibodies and their preparation
ES et al. RAHMENBAU-MUTIERTE ANTIKÖRPER UND IHRE HERSTELLUNG ANTICORPS A MUTATION DE SQUELETTE ET LEUR PREPARATION